Adjuvant Immunomodulatory (IM) Therapy
LTFU-ABO-102
Phase 3 small_molecule active
Quick answer
Adjuvant Immunomodulatory (IM) Therapy for Mucopolysaccharidosis IIIA is a Phase 3 program (small_molecule) at Ultragenyx UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx UK Limited
- Indication
- Mucopolysaccharidosis IIIA
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active